Source And Regulatory Documentation for DMID Clinical Studies
|
|
- Diane Short
- 6 years ago
- Views:
Transcription
1 Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007
2 Source Data Defined All information in original records and certified copies of original records. necessary for the reconstruction and evaluation of the trial. ICH GCP 1.51
3 Source Documents May Include: Hospital Records/Clinic charts Laboratory notes Memoranda Subject diaries X-rays Subject files ICH GCP 1.52
4 Why is Documentation of Source Data Necessary? For the reconstruction, evaluation and validation of clinical findings To substantiate integrity of trial data To confirm observations, existence of subjects To ensures data quality by creating an audit trail
5 Source Document Standards Aids in the establishment of a system of records Based on ICH/GCP, CFR, and guidances that apply to the involvement of Human Subjects Applicable to all DMID funded clinical trial sites
6 Correcting Records One line through, write new data, initial, date, and explain (if necessary) Changes made by person making initial entry or other authorized person Unacceptable correction methods Obliterations, correction fluid
7 Addenda to Source Documentation When Source Documentation is found to be incomplete (by site staff, monitor, auditor), document the deficiency in a chart note Addenda must be dated and initialed in real time in the Source Document Addenda must be made by research clinician presently responsible for the subject
8 CRF Tool to collect the data and provide a condensed picture of the participant s involvement in the study
9 When used as a Source Document Specific documents must be identified in the Protocol, MOP, or SD agreement before the study begins Must be signed, credentialed and dated CRF Site designed study forms must allow for free form text entry
10 Verbal: Communication Telephone verification of subject diagnoses or events with outside clinicians should be documented in a contact report or progress note Written: Correspondence must include appropriate study subject identifier's so monitor can verify that documents correspond to particular study subjects
11 Confidentiality SD Standards require: SDs may be identified with subject identifiers but CRFs must only contain PINs An ID Code List should be maintained to link the subject with the PIN and kept separate from the CRFs Records will remain confidential to the extent permitted by law Study information will not be released without subjects written permission Subject will not be personally identified in any publication about the study
12 Contraception Documentation Protocol-specific and/or IRB-required counseling must be documented Current form of contraception must be documented Informed Consent Form must be signed acknowledging any contraception requirements
13 Certified Copies A copy of original information that has been verified, by dated signature or initials and certification statement, that the document is an exact copy having all of the same attributes and information as the original
14 Certified Copies If an original document is retained off-site or within an institution, a copy needs to be certified There should be an identifier on the document indicating where the document originated Documentation received via FAX is not considered original, and must be certified
15 What do you do if the sending institution does not certify the copy? Receiving institution verifies the copy is unaltered as received Verifier must sign, or initial and date a statement on the copy indicating it is unaltered as received Statement may be in the form of a stamp, as long as it is accompanied by an original signature or initials and date
16 Death Documentation Verify date and cause of death with: Autopsy report Obituary Death Certificate If official documents are not available: Document verbal communication with a physician, study subject family member or friend to verify date and cause of death
17 What is a Protocol Deviation Any noncompliance to the Protocol, Good Clinical Practice (GCP), or protocol- specific Manual of Procedures Noncompliance may be either on the part of the subject, investigator, or study site staff. May result in significant added risk to the study subjects Interferes with the integrity of the data
18 Protocol Deviations Occur when there is non-adherence to the Protocol, including Informed Consent and Enrollment non-adherence. Examples: Missed visits Failure to obtain scheduled lab draw Administration of a non-allowable concomitant medication * DMID does not allow any exemptions or eligibility criteria wavers for enrollment.
19 Documenting Deviations Address in study subject Source Documentation Include reasons and prevention attempts
20 DMID Reporting Requirements Must be reported within 5 working days of identification of the protocol deviation, or within 5 working days of the scheduled protocol otocol- required activity 3 Ways to Report Protocol Deviations - Protocol Deviation Web Form - Protocol Deviation Print Form and Fax Cover Sheet - the Protocol Deviation Print Form and Fax Cover sheet
21 Reporting Deviations Sites must complete a copy of the DMID Protocol Deviation Form for each Protocol Deviation DMID Protocol Deviation Forms must be maintained in the Regulatory File as well as in the subject s s Source Documentation Copies of fax confirmation or e printout that Protocol Deviation Forms were submitted need to be included.
22 Electronic Medical Records Sites may either print out a copy of the medical records or provide access to an institutional computer for the monitor s s review Printout must include institutional name and date
23 End Point Criteria For study defined endpoints: Subject s s SD must document the specifics of the event and tests required by the protocol Print screen copy of electronic lab report with appropriate study subject identifiers, date of specimen collection, lab name, and date of printout Hard copy lab report from research/commercial lab with appropriate study subject identifiers and date of specimen collection Hard copy of correspondence that study subject has reached a study-defined defined lab-based based end point
24 Entry Criteria Documentation Address each specific entry criteria (Inclusion/Exclusion) Must be signed, credentialed, and dated by the enrolling clinician
25 Informed Consent Informed Consent must be signed and dated in ink by subject, parent/guardian/legally authorized representative prior to protocol screening Must correspond to the Protocol version approved by the IRB that was current at the time
26 Illiterate Parent/Guardian/Legally authorized representatives: Must have impartial witness during entire informed consent discussion All documents and written information must be read aloud and explained Allow opportunity for questions Must sign and personally date the consent form
27 Questionnaires Verify that the study subject completed the form per Protocol Evaluation Schedule by: Entering a note in the subject s s chart or CRF used as SD indicating the form used on a specified date Indicating on a checklist the subject- completed form on a specific date Including in the SD a copy of the subject- completed form that is signed and dated by the study personnel
28 Shadow Files Are certified copies of the subjects original lab reports, medical record, or clinical chart Are intended to reflect a complete study- specific record Monitors and auditors may request the original documents to verify validity of data or to look for unreported Adverse Events (AEs)
29 Medical Records that May be Included in a Shadow File Documentation of consent process Screening results Medical history/physical exam Vital status Clinical and lab findings Management of study drugs/agents and toxicities Concomitant medication
30 What are Toxicities? Toxicities are Adverse Events, Signs & Symptoms, or Abnormal Lab Results
31 Toxicities Must be documented in the CRF or in additional Source Documents For abnormal lab values, clinical significance must be documented by a responsible research clinician Research clinicians must note in the CRF/SD the relationship of the event to the Investigational Product unless otherwise specified in the Protocol
32 Urine Pregnancy Testing If your clinic/lab performs waived testing, but does not fall under a CLIA Certification of Compliance from a laboratory conducting moderate to high level testing, a CLIA Certificate of Waiver must be obtained Examples: Urine pregnancy tests Urinalysis
33 Urine Pregnancy Test Document When the test was done Test results Who performed or interpreted the results
34 Regulatory Documents Why Regulatory Documents are Required for Clinical Trials: Regulatory documents are submitted to track and evaluate the ethical and procedural conduct of a trial and the quality of the data that is produced Regulatory documents demonstrate the compliance of the Investigator, Sponsor and IRB/IEC with the standards of Good Clinical Practice and with all applicable regulatory requirements
35 Regulatory File Document Guidelines Investigators must maintain 1 file for each study, and all essential documents must be in the file Must be established at beginning of each study Updated throughout life of study Source for Guidelines ICH/GCP at 21 CFR 11, 50, etc. at 45 CFR 46 at
36 Initial Minimum Required For IND studies: Documents Form FDA 1572 Final signed/dated Protocol & Amendments IRB approved Informed Consent Form IRB approved advertisements IRB membership list or assurance number and compliance statement CVs for Principal Investigator (PI) and Sub-Investigators Laboratory Certifications and Normal Ranges Investigator s s Statement of Financial Disclosure for PI and Sub- Investigators Documentation of satisfactory site assessment (or waiver) Documentation of Protocol Training Signature Log
37 Form FDA 1572 Contract between FDA and Investigator Contains logistics such as names and addresses Section 9 Commitments of the Investigator orms/cder.html
38 Form FDA 1572 Signed/dated by Principal Investigator List names of all Sub-investigators Location of all sites where are subjects seen Section 4: List Clinical Laboratories ONLY Research laboratories must be identified in protocol Hand signed/dated on a double-sided form Keep ORIGINAL at site
39 Investigator Agreements Non-IND studies generally have an Investigator of Record (IOR) agreement Sometimes referred to as the investigator statement What is the PI agreeing to do?
40 Commitments of the PI/IOR Comply with protocol Ensure compliance of IRB and consent process with 45CFR 46 Report AEs Accurate record keeping and access No changes to study without permission of Sponsor and IRB
41 Financial Disclosure (IND Studies Only) Required for anyone listed on 1572 Documents any potential conflicts of interest regarding: Compensation Equity Proprietary information
42 Delegation of Responsibilities/Signature Log Who is required to be on this form? What s s the purpose?
43 Curriculum Vitae (CV) & Medical License All investigators and sub-investigators (listed on 1572 or IOR agreement) must submit a current CV and/or other relevant documents PI is responsible for maintaining the current licensure for all sub-investigators/study staff Maintain a copy of current medical licenses for the PI and all sub-investigators listed on the Form FDA 1572 in the regulatory file
44 Federal Wide Assurance (FWA) Obtained by Institution: Maintain a record of FWA number Expiration date Website for obtaining this information: UR
45 Protocol/Protocol Amendments Retain original IRB/IEC approved protocol and any approved revisions/amendments Draft protocols that were not submitted do not need to be maintained Remember to include version numbers and dates!!
46 Consent Forms Include a copy of original IRB approved consent and any subsequent IRB approved revisions/amendments Other consent forms: Screening consents Future use consents Translated consents
47 Advertisements and Subject Information Materials Types: TV Radio Newspaper Internet Flyers IRB approval must be obtained prior to the use of any study advertisement including revisions to advertisements
48 Submission Letter/Package/IRB/IEC Approval Includes: Full copies of original IRB-approved Protocol, subsequent approved revisions/amendments to Protocol. Maintain entire packets together in the file Including submission letter/package, responses,comments, and final IRB approval Everything should have a Version Number and date
49 IRB Approval Letter At minimum: (per GCP guideline 3.1.2) Protocol name and number Approval date List of approved documents
50 Periodic Reports/Annual Renewals Final Reports Submitted by the Principal Investigator to IRB: New safety information DSMB reports Annual renewals Final report Maintain all approvals with what was submitted
51 Study-Specific Specific Procedures or Manual of Procedures May include: Lab Procedures, Lab Specimen/Test Article handling and/or preparation instructions, and Protocol-specific instructions Each Study Specific Procedure (SOP) or Manual of Procedures (MOP) must have Version Number and Date All versions must be maintained in the regulatory file!!
52 Laboratory Normal Reference Ranges and Accreditations Must maintain current lab normal ranges used by all clinical labs for study data Laboratory name and date of the document must be provided Must maintain a copy of all labs current certifications Domestic laboratory certifications should include: CLIA accreditation and CAP or JCAHO, or CLIA certification of compliance (stand alone), or Dept. of Health cert. (if CLIA-exempt state) Research Labs (no accreditation required) CLIA exemptions for certain tests Non-US labs - include national equivalent of certification
53 Test Article Accountability Records The following documentation MUST be included with the Essential Documents: Shipping Receipts Receipt date, quantity Lot numbers Copy of test article label Record showing all UNUSED test article has been returned to designated central repository or manufacturer, or destroyed as per the IND sponsor s instructions Should include date of shipment (or destruction), quantity, and lot number of the returned or destroyed study material Transfer of Test Article from one study to another is not allowed
54 Investigator s Brochure/Package Insert Must be available to all study staff This is the site s s reference to potential reactions and side effects IND safety reports must be filed with the Investigator s s Brochure Any other informational letters issued by the manufacturer must be filed with the Investigator s s Brochure
55 Subject Screening/Enrollment Log All subjects screened for the study must be on the screening/enrollment log Subjects can not be screened until they have signed an informed consent document A study number or screening number must be used List reason why subject was not enrolled, when applicable
56 ID Code List Confidential document Remains at the site Study use only Contains names of all subjects allocated study numbers upon enrollment Contains subject contact information Allows investigator/institution to reveal the identity of any subject
57 Specimen Retention Records Maintain a record of the Protocol-specified retained body fluids/tissue samples (if any) to document the location and identification of retained samples if assays need to be repeated Sites must consult with DMID regarding the relocation, destruction, or anonymization of any remaining clinical specimens once study is complete and final report has been submitted to FDA. Unused specimens must be destroyed or anonymized unless consent has been granted for future use of stored specimens.
58 Serious Adverse Event Reporting Maintain copies of all SAE report forms in your regulatory binder SAEs determined to be causally related, serious, and unexpected MUST be reported immediately to the IRB, Sponsor and FDA (usually done by sponsor) IND sponsor may also send sites IND safety reports Must be submitted to the IRB Are considered amendments to the IB May require revision to informed consent
59 Temperature Log Maintain temperature log for all refrigerators/ freezers that hold study related materials Use a separate log for each refrigerator/ freezer study-related items
60 Monitor Log/Monitoring Reports List all study site visits made by external monitors and retain a copy of all site visit letters and reports This is proof that the site permits monitoring of their data
Regulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationNational Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services
National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services The Division of Microbiology and Infectious Diseases (DMID), National Institute
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationRegulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationInvestigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationPresented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationSELF-ASSESSMENT CHECKLIST
SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More informationImplementing Good Clinical Practice at an Academic Research Institution
Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationClinical Trials Management for Molecular Diagnostics. April 2016
Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationInvestigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationHuman Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance
Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify
More informationInvestigator s Responsibility
Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationFDA Audit Preparation
Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More informationORC Sponsor-Investigator IDE Checklist
A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationOFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out
OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More informationPreparing for Close-Out of Studies and Sites
Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationConducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency
Conducting and reporting a GCP Inspection Gunnar Danielsson Medical Products Agency Preparation for an inspection Inspection plan Create worksheets for the inspection general project specific study specific
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:
More informationGCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018
1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Specimen Management
Study Management SM 308.01 STANDARD OPERATING PROCEDURE FOR Specimen Management Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick M. Schnell, MD, FACP
More informationVanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
December 8, 2016 C2012 Web Seminar Series Identifying and Reporting Protocol Deviations Vanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
More informationShow Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH
Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH Speakers Kelly Dornin-Koss, MPPM, RN, CCRC Director Education and Compliance for Human
More informationClinical Trial Basics:
Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial
More informationTrial Master File. SOP No. SOP 7
Trial Master File SOP Title Trial Master File SOP No. SOP 7 Author Consultation Departments Date approved Julia Farmery Lincolnshire Clinical Research Facility, Research and Development, Trust consultants
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More informationRegulatory Visits, Audits and Investigations
Regulatory Visits, Audits and Investigations The Role of the Compliance Officer Carole A. Klove, JD, RN, CHRC Juliann Tenney, JD, CHRC Welcome! The content of this presentation does not necessarily represent
More informationICH/GCP Guidelines Self-Evaluation Questionnaire
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees
More informationUS Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
More informationUC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationSt. Luke s University Health Network
Page 1 of 6 PURPOSE: This standard operating procedure (SOP) serves as a companion to the Standard Operating Procedure for Data Management. The St. Luke s University Health Network (SLUHN) Clinical Trials
More informationand Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
More informationand Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationSponsoring an IND? Ignorance is Not Always Blissful
Translational Science 2013 Navigating The FDA Regulatory Landscape April 19, 2013 Washington D.C. Sponsoring an IND? Ignorance is Not Always Blissful Lisa A. Speicher, Ph.D Director, Clinical Trials Office
More informationDetails: Approval: Distribution & Storage:
Details: Author: Neville Young Quality Assurance Manager SOP Pages: Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person approving
More informationData Quality and Integrity: From Clinical Monitoring to Marketing Approval
Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationMEDICINES CONTROL COUNCIL
Clinical Trial Application Form MEDICINES CONTROL COUNCIL APPLICATION TO CONDUCT A CLINICAL TRIAL Study title Protocol No. Version No. Study Drug MCC Ref. no. (if applicable) MCC Ref number(s) of comparator
More informationStandard Operating Procedure
Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow
More informationAldrey Oliveira June 2nd 2016 Rio de Janeiro - Brazil
Quality Management Systems Clinical Trial Aldrey Oliveira June 2nd 2016 Rio de Janeiro - Brazil Different types of Clinical Research Treatment: Also called clinical trials generally involves an intervention
More informationVCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
More informationGOOD CLINICAL PRACTICE (GCP) Series Catalog
GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational
More informationFDA Audit Preparation
Duke University Ethics and Compliance Office FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Director, CTQA Agenda External audits Best practices to get ready for audits 2 External Audits
More informationSponsor/Investigator Responsibilities
Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationClinical Research & ICH GCP E6(R2) (Basic / Refresher Training):
Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Principles of GCP, Investigator Responsibilities, Essential Documents v3 01-Feb-2017 Objectives To provide refresher training on ICH GCP
More informationGCP Convergence Improves Transportability of Medical Device Clinical Data
GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled
More informationIND Development Process Published on ResearchGo UCLA (
IND Development Process IND Development Overview The Pre-IND Process The IND Study Protocol Preparing the Initial IND Submission Filing the IND Maintaining the IND IND Templates, Education and Useful Links
More informationCompassionate Use Navigator Information for Physicians
Compassionate Use Navigator Information for Physicians Contact: Elena Gerasimov, Program Director, Elena@kidsvcancer.org. As a physician, you must have wished there would be more treatment options for
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationHuman Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationClinical Evaluation Phases 1,2,3,4
Clinical Evaluation Phases 1,2,3,4 Matt Laurens, MD MPH Associate Professor of Pediatrics Center for Vaccine Development Institute for Global Health University of Maryland School of Medicine February 1,
More informationBy: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos,
By: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos, Email: aonyeaghala@ymail.com. Understand different regulations governing laboratory
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More information